Results from the national Myeloma XI trial have shown a higher incidence of second primary malignancies (SPM) in patients receiving Revlimid (lenalidomide) maintenance treatment compared to those who did not, in line with other previous reported trials. Published in the Blood Cancer Journal analysis of the data showed that, although the overall incidence of SPM was low, patients who were not eligible for high-dose therapy and stem cell transplantation and over the age of 74 were at greatest risk, with the highest incidence observed in this group. However, with ongoing monitoring the authors suggested that the benefits of Revlimid maintenance treatment were likely to outweigh the risk of developing SPM.


Read full article